Insights

Niche Market Focus DNAmito specializes in personalized cancer treatment through genomics, presenting a unique opportunity to partner with clinics and hospitals seeking advanced precision medicine solutions.

Innovative Technology The company's AI-driven decision support system and forthcoming DNA sequencing product demonstrate cutting-edge capabilities that can appeal to research centers and healthcare providers aiming to enhance treatment efficacy.

Emerging Market Potential With a small revenue base but engaging in innovative genomics, DNAmito is positioned to capture early adopters in the rapidly growing personalized medicine and genomics markets.

Collaborative Opportunities Partnerships with established genomics and health IT companies could accelerate product development and market entry, especially given the company's focus on integrating biological, genetic, and clinical data.

Funding and Growth prospects Although current revenue is modest, the company's development of next-generation diagnostics suggests significant growth potential, making it a compelling prospect for investors and strategic alliances.

DNAmito Tech Stack

DNAmito uses 8 technology products and services including WordPress, MySQL, Font Awesome, and more. Explore DNAmito's tech stack below.

  • WordPress
    Content Management System
  • MySQL
    Database
  • Font Awesome
    Font Scripts
  • Google Fonts API
    Font Scripts
  • jQuery
    Javascript Libraries
  • OWL Carousel
    Javascript Libraries
  • Bootstrap
    UI Frameworks
  • Apache
    Web Servers

Media & News

DNAmito's Email Address Formats

DNAmito uses at least 2 format(s):
DNAmito Email FormatsExamplePercentage
First@dnamito.comJohn@dnamito.com
50%
FL@dnamito.comJD@dnamito.com
33%
FMLast@dnamito.comJMDoe@dnamito.com
17%

Frequently Asked Questions

Where is DNAmito's headquarters located?

Minus sign iconPlus sign icon
DNAmito's main headquarters is located at 2225 East Bayshore Road Suite 200 Palo Alto, California 94303 United States. The company has employees across 1 continents, including North America.

What is DNAmito's official website and social media links?

Minus sign iconPlus sign icon
DNAmito's official website is prodecis.ai and has social profiles on LinkedIn.

What is DNAmito's NAICS code?

Minus sign iconPlus sign icon
DNAmito's NAICS code is 62 - Health Care and Social Assistance.

How many employees does DNAmito have currently?

Minus sign iconPlus sign icon
As of February 2026, DNAmito has approximately 3 employees across 1 continents, including North America. Key team members include Board Member: D. P.Member Board Of Directors: T. D.. Explore DNAmito's employee directory with LeadIQ.

What industry does DNAmito belong to?

Minus sign iconPlus sign icon
DNAmito operates in the Hospitals and Health Care industry.

What technology does DNAmito use?

Minus sign iconPlus sign icon
DNAmito's tech stack includes WordPressMySQLFont AwesomeGoogle Fonts APIjQueryOWL CarouselBootstrapApache.

What is DNAmito's email format?

Minus sign iconPlus sign icon
DNAmito's email format typically follows the pattern of First@dnamito.com. Find more DNAmito email formats with LeadIQ.

When was DNAmito founded?

Minus sign iconPlus sign icon
DNAmito was founded in 2015.

DNAmito

Hospitals and Health CareCalifornia, United States2-10 Employees

DNAmito is on the mission to personalize cancer treatment planning based on genomics.

PRODECIS is a clinical-grade decision support system for the personalized treatment of cancer. The AI-based predictive models are based on toxicity, tumor control, quality of life and cost-effectiveness.  Prodecis uses multiple factors such as biological, genetic, clinical and imaging data to compare various treatment options. Prodecis helps radiation oncologists select the best treatment path for each patient.

MITOTx is The Next Generation Predictive DNA sequencing product currently under development: Saliva-based SNP / mitochondrial DNA test to assess the risk of radiation-induced toxicity.  

The current clinical practice in radiation therapy does not differentiate the dose for each patient. The genetic test gives a reliable indication of the complication risk of radiation toxicity and thereby direct the patients to the type of radiation therapy that minimizes radiation to healthy tissue. It also indicates the possibility of a higher dose when the patient can tolerate it, thereby increasing the effectiveness of treatment.

Section iconCompany Overview

Headquarters
2225 East Bayshore Road Suite 200 Palo Alto, California 94303 United States
NAICS Code
62 - Health Care and Social Assistance
Founded
2015
Employees
2-10

Section iconMedia & News

Section iconFunding & Financials

  • $1M

    DNAmito's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1M

    DNAmito's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.